.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ESTIMABL2 randomized trial evaluated whether low-risk differentiated thyroid cancer could be managed safely after thyroid surgery without routine radioactive iodine. Patients were randomized to a follow-up strategy with no radioactive iodine or to ablation with radioactive iodine, with outcomes assessed over long-term follow-up. At five years, event-free survival in the no-radioiodine group was non-inferior to the radioiodine strategy. This provides important evidence that many patients with low-risk disease may not need routine postoperative radioactive iodine, avoiding treatment that can add burden, monitoring requirements and potential adverse effects without clear oncological benefit. For endocrine surgeons, the study reinforces the importance of accurate risk stratification and complete postoperative assessment. The decision is not simply about whether a patient has thyroid cancer, but about the biological and pathological features that determine recurrence risk. The practical implication is a more selective approach to adjuvant therapy. Surgery remains the foundation of treatment, but the extent of additional therapy should be matched to risk rather than applied automatically. ESTIMABL2 therefore contributes to a broader shift toward personalized thyroid cancer care, where avoiding overtreatment is itself an important clinical outcome.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ESTIMABL2 randomized trial evaluated whether low-risk differentiated thyroid cancer could be managed safely after thyroid surgery without routine radioactive iodine. Patients were randomized to a follow-up strategy with no radioactive iodine or to ablation with radioactive iodine, with outcomes assessed over long-term follow-up. At five years, event-free survival in the no-radioiodine group was non-inferior to the radioiodine strategy. This provides important evidence that many patients with low-risk disease may not need routine postoperative radioactive iodine, avoiding treatment that can add burden, monitoring requirements and potential adverse effects without clear oncological benefit. For endocrine surgeons, the study reinforces the importance of accurate risk stratification and complete postoperative assessment. The decision is not simply about whether a patient has thyroid cancer, but about the biological and pathological features that determine recurrence risk. The practical implication is a more selective approach to adjuvant therapy. Surgery remains the foundation of treatment, but the extent of additional therapy should be matched to risk rather than applied automatically. ESTIMABL2 therefore contributes to a broader shift toward personalized thyroid cancer care, where avoiding overtreatment is itself an important clinical outcome.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
